1. Home
  2. CRBU vs SWKH Comparison

CRBU vs SWKH Comparison

Compare CRBU & SWKH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRBU
  • SWKH
  • Stock Information
  • Founded
  • CRBU 2011
  • SWKH 1996
  • Country
  • CRBU United States
  • SWKH United States
  • Employees
  • CRBU N/A
  • SWKH N/A
  • Industry
  • CRBU Medicinal Chemicals and Botanical Products
  • SWKH Diversified Financial Services
  • Sector
  • CRBU Health Care
  • SWKH Finance
  • Exchange
  • CRBU Nasdaq
  • SWKH Nasdaq
  • Market Cap
  • CRBU 188.8M
  • SWKH 179.1M
  • IPO Year
  • CRBU 2021
  • SWKH 1999
  • Fundamental
  • Price
  • CRBU $1.93
  • SWKH $14.75
  • Analyst Decision
  • CRBU Strong Buy
  • SWKH Strong Buy
  • Analyst Count
  • CRBU 3
  • SWKH 1
  • Target Price
  • CRBU $6.67
  • SWKH $18.00
  • AVG Volume (30 Days)
  • CRBU 1.0M
  • SWKH 14.0K
  • Earning Date
  • CRBU 08-12-2025
  • SWKH 08-14-2025
  • Dividend Yield
  • CRBU N/A
  • SWKH N/A
  • EPS Growth
  • CRBU N/A
  • SWKH 55.18
  • EPS
  • CRBU N/A
  • SWKH 1.41
  • Revenue
  • CRBU $9,121,000.00
  • SWKH $37,409,000.00
  • Revenue This Year
  • CRBU $9.23
  • SWKH $52.93
  • Revenue Next Year
  • CRBU N/A
  • SWKH N/A
  • P/E Ratio
  • CRBU N/A
  • SWKH $10.21
  • Revenue Growth
  • CRBU N/A
  • SWKH 47.31
  • 52 Week Low
  • CRBU $0.66
  • SWKH $12.00
  • 52 Week High
  • CRBU $3.00
  • SWKH $16.24
  • Technical
  • Relative Strength Index (RSI)
  • CRBU 56.96
  • SWKH 51.35
  • Support Level
  • CRBU $1.80
  • SWKH $14.38
  • Resistance Level
  • CRBU $2.16
  • SWKH $14.80
  • Average True Range (ATR)
  • CRBU 0.14
  • SWKH 0.27
  • MACD
  • CRBU 0.00
  • SWKH 0.02
  • Stochastic Oscillator
  • CRBU 73.28
  • SWKH 78.12

About CRBU Caribou Biosciences Inc.

Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.

About SWKH SWK Holdings Corporation

SWK Holdings Corp is a healthcare capital provider. The company offers financing solutions to various life science companies, institutions, and inventors. It involves monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. Through its wholly-owned subsidiary, it also provides non-discretionary investment advisory services to institutional clients. The company's operating segments are Finance Receivables and Pharmaceutical Development Services. It generates maximum revenue from the Finance Receivables segment.

Share on Social Networks: